Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

Obesity Research

Volumn 7, Issue 4, 1999, Pages 313-322

  Ryan, Donna H ^a   Bray, George A ^a   Helmcke, Fred ^b   Sander, Gary ^b   Volaufova, Julia ^a   Greenway, Frank ^a   Siibramaniam, Pramilla ^b   Glancy, D Luke ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Appetite suppressants; Dexfenfluramine; Fenfluramine; Valvular regurgitation with medication; Valvulopathy

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; PHENTERMINE;

AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CHEMICALLY INDUCED DISORDER; COUNSELING; DRUG COMBINATION; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; OBESITY; OBSERVER VARIATION; PREVALENCE; WEIGHT REDUCTION;

AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; BODY MASS INDEX; COUNSELING; DEXFENFLURAMINE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; FENFLURAMINE; HUMANS; INCIDENCE; MALE; MAZINDOL; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBESITY; OBSERVER VARIATION; PHENTERMINE; PREVALENCE; WEIGHT LOSS;

EID: 0033162130     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1999.tb00414.x     Document Type: Article

References (10)

1. Connolly HM, Crary JL, McGoon, MD, Hensrud, DD, Edwards BS, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337:581-8.
2. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine (letter). W Engl J Med. 1997;337:635.
3. Anonymous. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations. November 1997. MMWR. 1997;46:1061-6.
4. Langreth R, Johannes L. Diet-drug mystery grows as new data emerge. The Wall Street Journal, October 31, 1997, Bl.
5. Wadden TA, Berkovritz RI, Silvestry F, et al. The Fen-Phen finale: a study of weight loss and valvular heart disease. Obes Res. 1998;6:278-84.
6. Khan MA, Herzog CA, St. Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. TV Engl J Med. 339:713-8.
7. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:725-32.
8. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto S. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol. 1987;S:952-9.
9. Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation. 1987;75:175-83.
10. Singl JP, Evans J, Levy D, et al. Framingham Heart Study (Abst#3033). Circulation. 1997;96:1541